Elizabeth Cairns

$ZEAL finally got its petre partner - and it's *drumroll* $RHHBY! $1.4B upfront, $5.3 in biobucks. Not bad. https://t.co/aO0dqVKagS

Happy new year! My first @endpts article of 2025 looks at how obesity pills - potentially the next big market - stack up: https://t.co/YA8iXzqCTi https://t.co/jzIej5SxMM

Now updated and with new version of the chart! $NVO $LLY $VKTX $RHHBY https://t.co/t81YXZzq7M

Endpoints News @endpts

BREAKING: Novo Nordisk's CagriSema fails to hit 25% weightloss benchmark in Phase 3 readout. Novo’s stock $NVO crashed by as much as 26% pre-market Friday. https://t.co/koSAVi3xd7

RT @endpts: We've noticed a huge number of people in the science and medical community joining @bluesky . Endpoints and many of our journal…

$AMGN's MariTide data are finally out. Here's my preview of the readout from last month, which also looks at the terrifyingly high expectations for $NVO's cagrisema.

Elizabeth Cairns @ByLizC

ICYMI yesterday, I had a look at the Q4 obesity readouts coming for $NVO's cagrisema and $AMGN's MariTide. This is a paywall-free read, but arguably not a comfortable one. https://t.co/kJFO6YpMdY

Drug development is tricky, it turns out. Following AbbVie's blow-up in schizophrenia, my @PharmaScrip piece from September shows the projects that are still in the running: https://t.co/LvH8VEXCB0

Elizabeth Cairns @ByLizC

ICYMI, here's yesterday's piece for @PharmaScrip on the companies aiming to follow $BMY in schizophrenia: https://t.co/PFA11r4PjL https://t.co/NGG3oGY5pB

ICYMI yesterday, I had a look at the Q4 obesity readouts coming for $NVO's cagrisema and $AMGN's MariTide. This is a paywall-free read, but arguably not a comfortable one. https://t.co/kJFO6YpMdY

RT @ByLizC: ICYMI, here's yesterday's piece for @PharmaScrip on the companies aiming to follow $BMY in schizophrenia: https://t.co/PFA11r4P…

ICYMI, here's yesterday's piece for @PharmaScrip on the companies aiming to follow $BMY in schizophrenia: https://t.co/PFA11r4PjL https://t.co/NGG3oGY5pB

Obesity pill monlunabant turns out disappointing for $NVO. Better to stick to incretins, perhaps. My take for @PharmaScrip: https://t.co/Z4gy1xJCVh https://t.co/nRXGQeSNnS

#ESCCongress: $BAYN's Kerendia is odds-on for approval after succeeding in the FINEARTS-HF study - but will it be used in preference to the SGLT2s? https://t.co/VoZrm70EKC

#ESCCongress: $ALNY believes Amvuttra could be a first-line therapy for ATTR cardiomyopathy. But add-on to $PFE's Vyndamax/Vyndaqel could be a more likely use. My piece for @PharmaScrip https://t.co/i67Qu3E2vA

$LLY's tirzepatide looks highly impressive in MASH, according to today's EASL abstract drop. My piece for @PharmaScrip, featuring updated efficacy comparison graphs with the tirz readout and yesterday's $VKTX data: https://t.co/N3L4afCG5X